CRM

Cardiac Rhythm Management

Cumulative Survival Probability

Pacemakers, ICDs, Leads

Product Performance Report
January 2009

BIOTRONIK
excellence for life

Product Performance Report

January 2009

Cardiac Rhythm Management

Pacemakers

ICDs

Leads

BIOTRONIK
excellence for life

Contents

1. Quality Excellence

BIOTRONIK has a long history of superior quality in product design and performance. For over 40 years, the name BIOTRONIK has been synonymous with excellent workmanship and superior patient safety. Our quality concept follows an integrated approach and extends from preventative risk measures during a product's development phase through all the steps of the manufacturing and design process.

BIOTRONIK's quality assurance system guarantees strict adherence to internal quality standards as well as compliance with international standards and guidelines. Regular reviews of our product performance and manufacturing evaluations contribute significantly to the achievement of extraordinary quality. Our customers, patients, and physicians can rely on the highest degree of safety built into our products. We always welcome suggestions from users about how we can improve the quality of our products.

This Product Performance Report is an integral component of BIOTRONIK's commitment to provide detailed, accurate information regarding long term reliability. The Product Performance Report exemplifies BIOTRONIK's policy of transparent and timely communication with our customers.

As a means to obtain continuous improvement of the designs, BIOTRONIK carefully analyzes returned products and incorporates all findings into our quality assurance system. This Product Performance Report was prepared in accordance with International Standard ISO 5841-2:2000 (E) and is in compliance with the recommendations from the U.S. Heart Rhythm Society Task Force on Device Performance Policies and Guidelines. As an active member of AdvaMed and their Pacemaker/ICD Working Group, BIOTRONIK has worked extensively with the CRM industry to ensure comparable product performance data is reported by all manufacturers. The data provided in BIOTRONIK's Product Performance Report incorporates the requirements and definitions as defined in AdvaMed's Requirements for Uniform Reporting of Clinical Performance of Pulse Generators, except as noted herein.

In BIOTRONIK's continuous efforts to provide accurate and transparent information and to ensure that a conservative estimate for device performance is reported, the Survival Probability calculations presented herein also consider reported pacemaker and ICD battery depletions as well as lead complications without the device having been returned for analysis.

Because a significant portion of this report is based on analyses of returned products, BIOTRONIK urges all physicians to return explanted devices and to notify us when a product is explanted or no longer in use for any reason.

BIOTRONIK aims to continually improve and enhance the scope of this report while integrating the latest information and data concerning the performance of our products. Please contact our U.S. Compliance Department (888) 345-0374 or Worldwide CRM Technical Service Department at +49-30-68905-2200 (Germany) with any comments, suggestions or questions. Your feedback is highly appreciated and will be used to further develop this report.

BIOTRONIK, January 2009

Arnold Kaspar
Vice President of Quality Management
BIOTRONIK GmbH & Co. KG

2. Terms and Definitions

The following terms and definitions are used for Pacemakers and Implantable Cardioverter Defibrillators (ICDs) throughout this Product Performance Report. These definitions form the basis for this Product Performance Report by clearly articulating the status of each device return and product analysis classification.

Elective Replacement Indicator

All active implantable devices that are powered by an internal battery need to be replaced when their battery is depleted. BIOTRONIK pacemakers and ICDs have an Elective Replacement Indicator (ERI) feature that notifies the health care provider when the device's battery is nearing the end of its useful life. Display of ERI is BIOTRONIK's recommendation to the user that the battery's present state will require device replacement in the near future. For further details please refer to the corresponding manual.

Battery Depletion

Battery depletions are classified as either normal (expected) or premature. Premature battery depletions are defined as device malfunctions, while normal battery depletions are not device malfunctions. Batteries of returned devices are considered to have depleted normally if they have reached their elective replacement indicator and testing indicates that the battery and associated circuitry are within specifications.

Out of Specification

Any component or software related event that causes the device's characteristics to not meet pre-defined performance specifications and requirements while implanted and in service. Returned product analysis that determines a device to be out of specification is considered a device malfunction. Normal battery depletions are not considered device malfunctions. BIOTRONIK defines the requirements and performance specifications for each product.

Device Malfunctions

Any component or software related event that causes the device's characteristics to be out of specification while implanted and in service are considered device malfunctions. Because it is impossible to verify that a device has malfunctioned without analyzing it, only returned devices can be classified as malfunctions for this report. Each returned device is analyzed to determine if it has malfunctioned. If the analysis determines that the device failed to meet its specifications while implanted and in service, it is further classified as either a malfunction with compromised therapy or as a malfunction without compromised therapy.

Devices damaged during implant, revision or after explant, damaged due to external causes (i.e., electrocautery) or to failure to follow instructions, warnings or contraindications in its associated technical manual are not considered malfunctions. Devices damaged due to interaction with other implanted devices (i.e., leads) are also not considered as malfunctions for the purposes of this Product Performance Report.

Malfunctions with Compromised Therapy

The condition when a pacemaker or ICD is found to have malfunctioned in a manner that compromised pacing or defibrillation therapy (including complete loss or partial degradation) while implanted and in service. Therapy is considered to have been compromised if critical patient-protective pacing or defibrillation therapy is not available.

Examples include: sudden loss of battery voltage; accelerated current drain such that a

depleted battery was not detected before loss of therapy; sudden malfunction during a tachycardia or fibrillation event resulting in aborted delivery of therapy; intermittent malfunction where therapy is sporadically unavailable.

Malfunctions without Compromised Therapy

The condition when a pacemaker or ICD is found to have malfunctioned in a manner that did not compromise pacing or defibrillation therapy while implanted and in service. Therapy is not compromised as long as critical patient-protective pacing and defibrillation therapies are available as determined through device analysis.

Unconfirmed Lead Complications

A lead performance issue where a complaint, associated with a specific clinical manifestation, is reported and where the lead is:

- Verified by medical records to have been implanted and in-service, and
- Implanted greater than 30 days, and
- Reported to have been removed from service,
- Modified to remedy the malfunction, or
- left in service based on medical judgment.

Examples include, but are not limited to: Abnormal pacing or defibrillation impedances, sensing anomalies, non-capture, discrepancy with mechanical integrity, perforation, and dislodgement.

Survival Probability Estimates

The probability that a device remains operational during a discrete time interval is defined as survival probability. Survival probability, as presented in this report, is related to device survival only and not survival of the patient. The survival probability estimates in this report are based on BIOTRONIK's analysis of returned products as well as events (e.g., ERI) that are reported to BIOTRONIK.

Cumulative Survival Probability Estimates

The survival probability over a device's service time is the cumulative survival probability. It is calculated from all discrete survival probabilities of previous time intervals. This characteristic is calculated separately for malfunction-free survival and all-cause survival (including normal battery depletions). Specific populations that are subject to a safety advisory notification are excluded and shown separately.

Implanted Devices

Only devices remaining implanted for at least one calendar day after the implantation date are considered as implanted. Devices that are removed from the patient on the same calendar day as the implant procedure do not contribute to the survival statistics.

Active Implants

The number of devices that remain operational within a discrete observation interval are active implants. Units are removed from this cohort due to patient death or explant for any reason.

Underreporting

A device status may change without being accounted for in the Product Performance database due to a lack of information being provided to BIOTRONIK. Underreporting adjustments deemed to be necessary are detailed in this report.

Safety Advisory Notifications

Any action taken by the manufacturer to inform clinicians concerning a device performance issue that may cause the device to not meet its predefined specifications is referred to as a Safety Advisory Notification.

3. Methodology for Pacemaker and ICD Survival Estimates

3.1 Cumulative Survival Probability

This report has been prepared in accordance with ISO 5841-2:2000 (E) applying actuarial analysis for the calculation of survival probabilities. Survival Estimates given in this report are considered to be generally representative for worldwide performance of BIOTRONIK devices.

The Cumulative Survival Probability is an estimate based on the percentage of pacemakers and ICDs that remain implanted and operational at various points of the product's service time in absence of concurrent events such as morbidity and voluntary explants for various reasons (e.g., device upgrade). The Device Survival Estimate over time is displayed in cumulative curves (Kaplan-Meyer). The product's performance is evaluated in discrete one-month intervals. The survival probability for each month is given by the number of devices that remain implanted and operational through this month divided by the number of devices that entered the interval. The cumulative survival probability for any period is given by multiplying all survival probabilities of previous months.

At the time of implantation, the cumulative survival probability is 100 %. Even though they are analyzed as part of our quality system monitoring, devices that are found to be out of specification prior to or during the implantation procedure are removed from the statistics as they do not contribute to a patient's risk of being subject to a device malfunction or replacement during the device's service time. Because this report is provided to describe product performance based on returned product analyses, the pacemaker and ICD data does not include information regarding medical complications such as erosion, infection or diaphragmatic stimulation.

In general, during the initial phase of the service time, devices which are out of specification are the primary contribution to reduction of survival probability. As the product lifecycle lengthens, normal battery depletion assumes a greater impact on the survival curve and becomes the dominating factor.

In order to make these two effects distinguishable, the cumulative survival probability curves are shown separately for devices that are confirmed to have malfunctioned only, and for total (all-cause) cumulative survival. In case of a device being subject to a safety advisory notification that significantly impacts the survival probability, this factor is displayed separately.

3.2 Data Acquisition

This report is based on the observation of BIOTRONIK's U.S. products through review of our device registration and tracking systems and analyses of returned products from all sources. Because the ability to perform decedent searches of patients with BIOTRONIK devices via the U.S. Social Security Administration, the use of U.S. data more accurately represents the active patient population for reporting purposes. In addition, device tracking regulations and vigilance reporting regulations vary throughout the world; therefore use of the U.S. data is most appropriate for accurate and consistent reporting of product performance.

In order to be included in the population under observation, a device must be registered and implanted for at least one calendar day. The cut-off date for the data included in this report is July 1, 2008. The number of U.S. devices that are implanted and remain active as well as the total number of products distributed worldwide are provided for each product family in this report. Information is provided for separate product families, in that devices with nearly identical hardware and therapy functions are combined. For example, Lexos VR and VR-T (with Home Monitoring) ICDs are combined into a single family, Lexos Single Chamber ICDs.

Survival estimates are calculated for product families having accumulated at least 1,000 cumulative implant months. Because 1,000 implant months may take some time to accumulate, there may be a gap between U.S. market release and the start of graphical representation of survival probability. Products no longer being distributed with less than 500 active implants may be excluded from this report.

ISO 5841-2 describes a method for adjusting the device survival probability to compensate for underreported malfunctions and unrelated patient deaths. The factor for underreporting of malfunctions is unknown as currently no systematic data is available that reveals this factor. Consequently, this factor remains unaccounted for in this report. Patient mortality is adjusted only if published rates for comparable patient populations differ significantly from the data provided by our registration and tracking systems.

3. Methodology for Pacemaker and ICD Survival Estimates

3.3 Returned Product Analysis

Information on malfunctioning for the pacemaker and ICD portions of this report is taken exclusively from the analysis of returned products. The outcome of this analysis is the basis for the final classification of the device's cause of explantation. Only analyzed products with confirmed device malfunctions are utilized in the calculation of malfunction-free survival probability.

Every pacemaker and ICD returned to BIOTRONIK is analyzed per internal procedures and classified as functioning normally, normal battery depletion, or malfunctioning (including premature battery depletion) while implanted and in service. These device classifications are the basis for BIOTRONIK's cumulative survival estimates on pacemakers and ICDs.

As a significant portion of pacemakers and ICDs with normal battery depletion are not returned for analysis, BIOTRONIK also considers unconfirmed pacemaker and ICD battery depletions (reported, but device not returned) in the total survival estimates to ensure that a conservative estimate for device performance is reported.

4. Product Performance Graphs and Data

The product performance information is shown in each section in alphabetical order and by product type.

For each product, the report provides:

- Product versions that contribute to the evaluation
- U.S. and CE market release dates
- Worldwide quantity of products that have been distributed
- U.S. registered implants (number of products included in this report)
- Estimated active U.S. implants

The survival plots provide:

1. Total survival:
The combined cumulative survival probability for all causes that result in device removal or a system out of operation, excluding removals for clinical reasons unrelated to the device's performance (i.e., infections).

2. Malfunction-Free Survival:
The cumulative survival probability free of component or software malfunctions excluding normal battery depletions, but including premature battery depletions. A depleted battery is classified as a premature depletion, if the device analysis confirms a component or software malfunction as cause for the early depletion. Normal battery depletions only have an impact on the total cumulative survival.

Products or subgroups of products may become subject to safety advisory notifications that can significantly impact the overall product performance. However, because these subgroups are clearly defined they are separated from the non-advisory devices. The impact of the advisory notification is then shown in a separate graph for total cumulative survival and for malfunction-free survival of the device population affected by the advisory notification.

The cumulative survival data and the 95 % confidence intervals according to the Greenwood's[1] formula are shown in numerical form for the observed population.

1 Greenwood, M. The natural duration of cancer. Reports on Public Health and Medical Subjects 33, London: Her Majesty's Stationery Office, 1–26, 1926.

5. Performance of BIOTRONIK Pacemakers

5.1 Single Chamber Pacemakers

5.2 Dual Chamber Pacemakers

Actros

Product Details

Product Versions	Actros S, Actros SR
NBG Code(s)	SSI, SSIR
U.S. Market Release	Mar 1998
CE Market Release	Apr 1997
Worldwide Distributed Devices	128,000
Registered U.S. Implants	6,740
Estimated Active U.S. Implants	1,980
Normal Battery Depletions	160
Confirmed Malfunctions	1
· Therapy Compromised	0
· Therapy Available	1



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	99.9	99.9	99.5	99.2	98.6	97.3	94.9	90.8	-
(95 % Confidence Interval)		±0.0	±0.1	±0.1	±0.2	±0.3	±0.4	±0.6	±1.0	±1.7	-
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	-
(95 % Confidence Interval)			±0.0	±0.0	±0.0	±0.0	±0.0	±0.0	±0.0	±0.0	-

Axios

Product Details

Product Versions	Axios S, Axios SR
NBG Code(s)	SSI, SSIR
U.S. Market Release	Nov 2001
CE Market Release	Oct 2001
Worldwide Distributed Devices	104,000
Registered U.S. Implants	1,360
Estimated Active U.S. Implants	639
Normal Battery Depletions	5
Confirmed Malfunctions	0
· Therapy Compromised	0
· Therapy Available	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	100.0	100.0	100.0	99.2	-	-	-	-	-
(95 % Confidence Interval)						±0.8	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	-	-	-	-	-
(95 % Confidence Interval)							-	-	-	-	-

Cylos

Product Details

Product Versions	Cylos VR
NBG Code(s)	VVIR
U.S. Market Release	Jan 2006
CE Market Release	Nov 2005
Worldwide Distributed Devices	10,700
Registered U.S. Implants	2,530
Estimated Active U.S. Implants	2,340
Normal Battery Depletions	0
Confirmed Malfunctions	0
· Therapy Compromised	0
· Therapy Available	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	100.0	-	-	-	-	-	-	-	-
(95 % Confidence Interval)				-	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	100.0	-	-	-	-	-	-	-	-
(95 % Confidence Interval)				-	-	-	-	-	-	-	-

Philos

Product Details

Product Versions	Philos S, Philos SR
NBG Code(s)	SSI, SSIR
U.S. Market Release	Sep 2000
CE Market Release	Aug 2000
Worldwide Distributed Devices	80,000
Registered U.S. Implants	5,320
Estimated Active U.S. Implants	2,950
Normal Battery Depletions	14
Confirmed Malfunctions	7
· Therapy Compromised	0
· Therapy Available	7



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.9	99.7	99.7	99.4	98.9	-	-	-	-
(95 % Confidence Interval)		±0.1	±0.1	±0.2	±0.2	±0.3	±0.5	-	-	-	-
Malfunction-Free Survival [%]	100.0	99.9	99.9	99.9	99.9	99.8	99.7	-	-	-	-
(95 % Confidence Interval)		±0.1	±0.1	±0.1	±0.1	±0.2	±0.3	-	-	-	-

Philos II and Talos

Product Details

Product Versions*	Philos II S, Philos II SR, Talos S, Talos SR
NBG Code(s)	SSI, SSIR
U.S. Market Release	Sep 2004
CE Market Release	Feb 2004/May 2006
Worldwide Distributed Devices	59,600
Registered U.S. Implants	2,940
Estimated Active U.S. Implants	2,490
Normal Battery Depletions	1
Confirmed Malfunctions	1
· Therapy Compromised	1
· Therapy Available	0

* While Talos SR and Talos S are not distributed in the U.S., their performance is expected to be similar to the U.S. distributed products



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	100.0	99.8	-	-	-	-	-	-	-
(95 % Confidence Interval)				±0.3	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	100.0	99.9	-	-	-	-	-	-	-
(95 % Confidence Interval)				±0.2	-	-	-	-	-	-	-

Protos

Product Details

Product Versions	Protos VR/CLS
NBG Code(s)	VVIR
U.S. Market Release	Jan 2003
CE Market Release	Jul 2003
Worldwide Distributed Devices	9,460
Registered U.S. Implants	3,250
Estimated Active U.S. Implants	2,140
Normal Battery Depletions	6
Confirmed Malfunctions	4
· Therapy Compromised	1
· Therapy Available	3



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	99.9	99.8	99.5	-	-	-	-	-	-
(95 % Confidence Interval)			±0.1	±0.2	±0.4	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	99.9	99.9	99.7	-	-	-	-	-	-
(95 % Confidence Interval)			±0.1	±0.1	±0.3	-	-	-	-	-	-

Actros

Product Details

Product Versions	Actros D, Actros DR, Actros SLR
NBG Code(s)	DDD, DDDR, VDDR
U.S. Market Release	Mar 1998
CE Market Release	Apr 1997
Worldwide Distributed Devices	110,000
Registered U.S. Implants	13,700
Estimated Active U.S. Implants	3,880
Normal Battery Depletions	2,044
Confirmed Malfunctions	3
· Therapy Compromised	3
· Therapy Available	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	99.9	99.8	99.1	97.0	91.4	81.9	71.3	62.2	-
(95 % Confidence Interval)		±0.0	±0.0	±0.1	±0.2	±0.3	±0.6	±0.9	±1.1	±1.5	-
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	-
(95 % Confidence Interval)		±0.0	±0.0	±0.0	±0.0	±0.0	±0.0	±0.0	±0.0	±0.0	-

Axios

Product Details

Product Versions	Axios D, Axios DR, Axios SLR
NBG Code(s)	DDD, DDDR, VDDR
U.S. Market Release	Nov 2001
CE Market Release	Oct 2001
Worldwide Distributed Devices	97,800
Registered U.S. Implants	2,720
Estimated Active U.S. Implants	1,600
Normal Battery Depletions	29
Confirmed Malfunctions	2
· Therapy Compromised	0
· Therapy Available	2



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	100.0	99.9	99.5	99.1	96.3	-	-	-	-
(95 % Confidence Interval)			±0.1	±0.2	±0.3	±0.5	±1.5	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	99.9	99.9	-	-	-	-
(95 % Confidence Interval)						±0.2	±0.2	-	-	-	-

Cylos

Product Details

Product Versions	Cylos DR, Cylos DR-T
NBG Code(s)	DDDR
U.S. Market Release	Jan 2006
CE Market Release	Nov 2005
Worldwide Distributed Devices	33,400
Registered U.S. Implants	11,200
Estimated Active U.S. Implants	10,700
Normal Battery Depletions	1
Confirmed Malfunctions	1
· Therapy Compromised	0
· Therapy Available	1



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	100.0	-	-	-	-	-	-	-	-
(95 % Confidence Interval)			±0.1	-	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	100.0	-	-	-	-	-	-	-	-
(95 % Confidence Interval)				-	-	-	-	-	-	-	-

Philos

Product Details

Product Versions	Philos D, Philos DR, Philos DR-T, Philos SLR
NBG Code(s)	DDD, DDDR, VDDR
U.S. Market Release	Sep 2000
CE Market Release	Aug 2000
Worldwide Distributed Devices	144,000
Registered U.S. Implants	19,500
Estimated Active U.S. Implants	12,300
Normal Battery Depletions	395
Confirmed Malfunctions	20
· Therapy Compromised	3
· Therapy Available	17



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	99.9	99.8	99.3	98.2	96.3	92.8	-	-	-
(95 % Confidence Interval)		±0.0	±0.0	±0.1	±0.1	±0.2	±0.4	±0.8	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	100.0	99.9	99.9	99.9	99.8	99.8	-	-	-
(95 % Confidence Interval)		±0.0	±0.0	±0.0	±0.1	±0.1	±0.1	±0.1	-	-	-

Philos II and Talos

Product Details

Product Versions*	Philos II D, Philos II DR(-T), Philos II SLR, Talos D, Talos DR, Talos SLR
NBG Code(s)	DDD, DDDR, VDDR
U.S. Market Release	Sep 2004
CE Market Release	Feb 2004/May 2006
Worldwide Distributed Devices	133,000
Registered U.S. Implants	13,700
Estimated Active U.S. Implants	12,200
Normal Battery Depletions	10
Confirmed Malfunctions	3
· Therapy Compromised	0
· Therapy Available	3

* While Philos II SLR, Talos D, Talos DR and Talos SLR are not distributed in the U.S., their performance is expected to be similar to the U.S. distributed products



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	99.9	99.8	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.0	±0.1	±0.1	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	100.0	99.9	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.0	±0.0	±0.1	-	-	-	-	-	-	-

Protos

Product Details

Product Versions	Protos DR/CLS
NBG Code(s)	DDDR
U.S. Market Release	Jan 2003
CE Market Release	Jul 2003
Worldwide Distributed Devices	26,600
Registered U.S. Implants	10,800
Estimated Active U.S. Implants	7,970
Normal Battery Depletions	153
Confirmed Malfunctions	4
· Therapy Compromised	0
· Therapy Available	4



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.9	99.6	98.7	94.7	-	-	-	-	-
(95 % Confidence Interval)		±0.0	±0.1	±0.1	±0.3	±0.9	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	-	-	-	-	-
(95 % Confidence Interval)		±0.0	±0.0	±0.0	±0.0	±0.0	-	-	-	-	-

6. Performance of BIOTRONIK ICDs



Lexos

Product Details

Product Versions	Lexos VR, Lexos VR-T
NBG Code(s)	VVIRD
Maximum Energy [J]	30
U.S. Market Release	Feb 2004
CE Market Release	Oct 2003
Worldwide Distributed Devices	13,400
Registered U.S. Implants	1,250
Estimated Active U.S. Implants	971
Normal Battery Depletions	4
Confirmed Malfunctions	0
· Therapy Compromised	0
· Therapy Available	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.8	99.5	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.2	±0.3	±0.5	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	-	-	-	-	-	-	-
(95 % Confidence Interval)					-	-	-	-	-	-	-

Lumax 340

Product Details

Product Versions	Lumax 340 VR-T
NBG Code(s)	VVIRD
Maximum Energy [J]	40
U.S. Market Release	Feb 2007
CE Market Release	Feb 2007
Worldwide Distributed Devices	4,680
Registered U.S. Implants	1,380
Estimated Active U.S. Implants	1,330
Normal Battery Depletions	1
Confirmed Malfunctions	2
· Therapy Compromised	1
· Therapy Available	1

Cumulative Survival Probability



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.7	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.3	-	-	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	99.8	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.2	-	-	-	-	-	-	-	-	-

Lumos

Product Details

Product Versions	Lumos VR-T
NBG Code(s)	VVIRD
Maximum Energy [J]	30
U.S. Market Release	Sep 2005
CE Market Release	May 2005
Worldwide Distributed Devices	5,890
Registered U.S. Implants	1,740
Estimated Active U.S. Implants	1,560
Normal Battery Depletions	1
Confirmed Malfunctions	0
· Therapy Compromised	0
· Therapy Available	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.9	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.1	±0.1	-	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	100.0	-	-	-	-	-	-	-	-
(95 % Confidence Interval)				-	-	-	-	-	-	-	-

Lexos

Product Details

Product Versions*	Lexos DR, Lexos DR-T, Lexos A+, Lexos A+/T
NBG Code(s)	DDDRD, VDDRD
Maximum Energy [J]	30
U.S. Market Release	Feb 2004
CE Market Release	Oct 2003
Worldwide Distributed Devices	9,550
Registered U.S. Implants	2,580
Estimated Active U.S. Implants	1,940
Normal Battery Depletions	46
Confirmed Malfunctions	5
· Therapy Compromised	1
· Therapy Available	4

* While Lexos A+ and Lexos A+/T are not distributed in the U.S., their performance is expected to be similar to the U.S. distributed products



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.8	99.6	98.4	95.5	-	-	-	-	-	-
(95 % Confidence Interval)		±0.2	±0.2	±0.6	±1.5	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	99.9	99.8	99.8	99.8	-	-	-	-	-	-
(95 % Confidence Interval)		±0.1	±0.2	±0.2	±0.2	-	-	-	-	-	-

Lumax 300

Product Details

Product Versions	Lumax 300 DR-T
NBG Code(s)	DDDRD
Maximum Energy [J]	30
U.S. Market Release	Feb 2007
CE Market Release	Feb 2007
Worldwide Distributed Devices	1,470
Registered U.S. Implants	204
Estimated Active U.S. Implants	197
Normal Battery Depletions	0
Confirmed Malfunctions	0
· Therapy Compromised	0
· Therapy Available	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	-	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		-	-	-	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	-	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		-	-	-	-	-	-	-	-	-	-

Lumax 340

Product Details

Product Versions	Lumax 340 DR-T
NBG Code(s)	DDDRD
Maximum Energy [J]	40
U.S. Market Release	Feb 2007
CE Market Release	Feb 2007
Worldwide Distributed Devices	6,810
Registered U.S. Implants	2,580
Estimated Active U.S. Implants	2,470
Normal Battery Depletions	0
Confirmed Malfunctions	1
· Therapy Compromised	1
· Therapy Available	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)			-	-	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)			-	-	-	-	-	-	-	-	-

Lumos

Product Details

Product Versions	Lumos DR-T
NBG Code(s)	DDDRD
Maximum Energy [J]	30
U.S. Market Release	Sep 2005
CE Market Release	May 2005
Worldwide Distributed Devices	5,260
Registered U.S. Implants	2,180
Estimated Active U.S. Implants	1,910
Normal Battery Depletions	6
Confirmed Malfunctions	3
· Therapy Compromised	1
· Therapy Available	2



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.5	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.1	±0.3	-	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	99.9	99.9	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.1	±0.1	-	-	-	-	-	-	-	-

Xelos

Product Details

Product Versions	Xelos DR-T
NBG Code(s)	DDDRD
Maximum Energy [J]	36
U.S. Market Release	May 2005
CE Market Release	May 2005
Worldwide Distributed Devices	1,120
Registered U.S. Implants	535
Estimated Active U.S. Implants	448
Normal Battery Depletions	3
Confirmed Malfunctions	4
· Therapy Compromised	1
· Therapy Available	3



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.6	98.0	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.5	±1.3	-	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	98.8	-	-	-	-	-	-	-	-
(95 % Confidence Interval)			±1.2	-	-	-	-	-	-	-	-

Kronos

Product Details

Product Versions	Kronos LV-T
NBG Code(s)	DDDRD
Maximum Energy [J]	30
U.S. Market Release	Aug 2006
CE Market Release	Dec 2004
Worldwide Distributed Devices	2,930
Registered U.S. Implants	430
Estimated Active U.S. Implants	372
Normal Battery Depletions	4
Confirmed Malfunctions	1
· Therapy Compromised	0
· Therapy Available	1



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.8	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.5	-	-	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	99.8	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.5	-	-	-	-	-	-	-	-	-

Lumax 340

Product Details

Product Versions	Lumax 340 HF-T
NBG Code(s)	DDDRD
Maximum Energy [J]	40
U.S. Market Release	Feb 2007
CE Market Release	Dec 2006
Worldwide Distributed Devices	5,960
Registered U.S. Implants	1,980
Estimated Active U.S. Implants	1,880
Normal Battery Depletions	3
Confirmed Malfunctions	0
· Therapy Compromised	0
· Therapy Available	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.7	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.4	-	-	-	-	-	-	-	-	-
Malfunction-Free Survival [%]	100.0	100.0	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)			-	-	-	-	-	-	-	-	-

7. X-Ray Identifiers for Pacemakers and ICDs

Pacemaker/ICD Product Versions	X-Ray ID
Actros DR, Actros D, Actros SLR, Actros SR, Actros S	LC
Axios DR, Axios D, Axios SLR, Axios SR, Axios S	ER
Cylos DR, Cylos DR-T	RZ
Kronos LV-T	FL
Lexos DR, Lexos DR-T, Lexos A+, Lexos A+/T, Lexos VR, Lexos VR-T	KV
Lumax 300 DR-T, Lumax 340 DR-T, Lumax 340 HF-T, Lumax 340 VR-T	HR
Lumos DR-T, Lumos VR-T	LT
Philos DR, Philos D, Philos SLR, Philos SR, Philos S	LE
Philos DR-T	VV
Philos II DR, Philos II D, Philos II S, Philos II SLR, Philos II SR	ET
Philos II DR-T	KP
Talos DR, Talos D, Talos SLR, Talos SR, Talos S	PV
Protos DR/CLS, Protos VR/CLS	EZ
Xelos DR-T	CT

8. Methodology for Lead Survival Estimates

8.1 Cumulative Lead Survival Probability

This report has been prepared in accordance with ISO 5841-2:2000 (E) applying actuarial analysis for the calculation of lead survival probabilities. Lead Survival Estimates given in this report are considered to be generally representative for worldwide performance of BIOTRONIK's pacing and ICD leads.

The Cumulative Survival Probability for leads is an estimate based on the percentage of devices that remain implanted and in service at various points of the product's service time in the absence of concurrent events such as morbidity. The Lead Survival Estimate over time is displayed in cumulative survival curves (Kaplan-Meyer). The product's performance is evaluated in discrete one-month intervals. The survival probability for each month is given by the number of leads that remain implanted and active through this month divided by the number of leads that were actively implanted at the start of the interval. The cumulative survival probability for any period is given by multiplying all survival probabilities of previous months.

At the time of implantation, the cumulative lead survival probability is 100 %. Even though they are analyzed as part of our quality system monitoring, leads that are found to be out of specification prior to or during the implantation procedure are removed from the statistics as they do not contribute to a patient's risk of being subject to a device malfunction or replacement during the device's service time.

Because this report is provided to communicate information regarding product performance, it does not include data regarding medical complications such as erosion, infection or diaphragmatic stimulation.

Compared to pacemakers and ICDs, a considerable portion of leads with observed or suspected failures are not explanted and returned for laboratory analysis. This is primarily because it is much more difficult and risky to the patient to remove chronically implanted leads. In order to report a conservative measure of lead performance, unconfirmed reports of lead complications are therefore also included in the calculation of a lead's survival probability. In order to be classified as an unconfirmed lead complication and thus contributing to the survival probability calculation the same way as a confirmed malfunction, the reported anomaly must have occurred at least 30 days post-implant. Otherwise, factors not related to the lead would likely be the root cause of the observed anomaly, (i.e., patient-specific conditions or implant techniques).

In order to minimize the effect of underreporting of lead malfunctions, BIOTRONIK is currently analyzing the usefulness of including long-term, post-market studies of our pacing and ICD leads to establish improved measurements of lead performance.

8.2 Lead Data Acquisition

The following sections of this report provide performance data on BIOTRONIK's pacing and ICD leads and are based on the observation of BIOTRONIK's U.S. products through review of our device registration and tracking systems, and through the analyses of both, returned leads as well as reports of lead complications of non-returned leads.

In order to be included in the population under observation a lead must be registered and implanted for at least one calendar day. The cut-off date for the data included in this report is July 1, 2008. The sample sizes of U.S. leads that are implanted and remain active as well as the total number of products distributed worldwide are provided for each lead family in this report.

Survival estimates are calculated for lead families having accumulated at least 1,000 cumulative implant months. Products no longer being distributed with less than 500 active implants may be excluded from this report.

ISO 5841-2 (E) describes a method for adjusting the device survival probability for underreported malfunctions and unrelated patient deaths that result in an overestimation of the device's survival probability. The factor for U.S. underreporting of malfunctions of pacing and ICD leads is unknown as currently no systematic data is available that reveals this factor. Consequently, this factor remains unaccounted for in this report. Patient mortality is adjusted only if published rates for comparable patient populations differ significantly from the data provided by our registration and tracking systems.

8. Methodology for Lead Survival Estimates

8.3 Returned Product Analysis

Information for the lead sections of this report is taken from the analysis of returned products. The outcome of this analysis is the basis for the final classification of the cause for explantation of the lead. Additionally, reports of lead complications not confirmed by laboratory analysis are taken into consideration. Both, leads with confirmed malfunctions as well as unconfirmed lead complications decrease a lead's total survival probability.

Every lead and lead segment returned to BIOTRONIK is analyzed per our internal procedures and classified as within specification, damaged by external causes, or out of specification (malfunction) while implanted and in service.

9. Lead Product Performance Graphs and Data

The lead performance information is shown in each section in alphabetical order and by product name.

For each lead, the report provides:

- Product versions that contribute to the evaluation
- Types of leads
- CE and U.S. market release dates
- Worldwide quantity of products that have been distributed
- U.S. registered implants (number of products included in this report)
- Estimated active U.S. implants

The survival plots provide:
Total survival: The cumulative survival probability free of component malfunction or unconfirmed observation of an anomaly. Removals for clinical reasons unrelated to the device's performance (i.e., infections) are excluded.

Products or subgroups of products may become subject to advisory notifications that can significantly impact the overall product performance. To date, BIOTRONIK has never had a pacing or ICD lead safety advisory notification, therefore no summary of advisories is provided.

The cumulative survival data and the 95 % confidence intervals according to the Greenwood's formula[2] are shown in numerical form for the observed sample population.

2 Greenwood, M. The natural duration of cancer. Reports on Public Health and Medical Subjects 33, London: Her Majesty's Stationery Office, 1–26, 1926

10. Performance of BIOTRONIK Leads

Arox

Product Details

Product Versions	Arox 53-BP, Arox 60-BP
Lead Type	straight, passive fixation
U.S. Market Release	Sep 2002
CE Market Release	Jan 2002
Worldwide Distributed Devices	30,700
Registered U.S. Implants	7,860
Estimated Active U.S. Implants	5,850
Unconfirmed Complications	0
Confirmed Malfunctions	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	-	-	-	-	-
(95 % Confidence Interval)							-	-	-	-	-

Arox J

Product Details

Product Versions	Arox 45-JBP, Arox 53-JBP
Lead Type	J-shape, passive fixation
U.S. Market Release	Sep 2002
CE Market Release	Jan 2002
Worldwide Distributed Devices	7,460
Registered U.S. Implants	2,980
Estimated Active U.S. Implants	2,390
Unconfirmed Complications	0
Confirmed Malfunctions	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	100.0	100.0	100.0	-	-	-	-	-	-
(95 % Confidence Interval)						-	-	-	-	-	-

Corox

Product Details

Product Versions	Corox OTW 75-UP Steroid, 85-UP Steroid
Lead Type	unipolar, helix fixation
U.S. Market Release	Aug 2006
CE Market Release	Apr 2004
Worldwide Distributed Devices	8,070
Registered U.S. Implants	1,380
Estimated Active U.S. Implants	1,230
Unconfirmed Complications	13
Confirmed Malfunctions	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.0	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.6	-	-	-	-	-	-	-	-	-

Dextrus

Product Details

Product Versions	Dextrus Model 4135, 4136, 4137
Lead Type	straight, passive fixation, bipolar
U.S. Market Release	Apr 2007
CE Market Release	May 2007
Worldwide Distributed Devices	53,000
Registered U.S. Implants	35,700
Estimated Active U.S. Implants	33,800
Unconfirmed Complications	185
Confirmed Malfunctions	3



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.1	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.1	-	-	-	-	-	-	-	-	-

Elox

Product Details

Product Versions	Elox 45-BP, 53-BP, 60-BP
Lead Type	straight, active fixation
U.S. Market Release	May 2000
CE Market Release	May 2000
Worldwide Distributed Devices	36,000
Registered U.S. Implants	11,000
Estimated Active U.S. Implants	5,880
Unconfirmed Complications	27
Confirmed Malfunctions	2



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.8	99.8	99.8	99.8	99.7	99.7	99.6	-	-	-
(95 % Confidence Interval)		±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	-	-	-

Elox P

Product Details

Product Versions	Elox P 45-BP, 53-BP, 60-BP
Lead Type	straight, active fixation
U.S. Market Release	May 2003
CE Market Release	Feb 2003
Worldwide Distributed Devices	21,900
Registered U.S. Implants	3,030
Estimated Active U.S. Implants	2,050
Unconfirmed Complications	2
Confirmed Malfunctions	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	100.0	100.0	100.0	-	-	-	-	-	-
(95 % Confidence Interval)			±0.1	±0.1	±0.1	-	-	-	-	-	-

Polyrox

Product Details

Product Versions	Polyrox 60-UP, 53-BP, 53/15-BP, 60-BP, 60/15-BP
Lead Type	straight, passive fixation
U.S. Market Release	Mar 1997
CE Market Release	Jul 1996
Worldwide Distributed Devices	312,000
Registered U.S. Implants	15,100
Estimated Active U.S. Implants	6,800
Unconfirmed Complications	2
Confirmed Malfunctions	1



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.
Total Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.9	99.9	99.9	-
(95 % Confidence Interval)					±0.0	±0.0	±0.0	±0.0	±0.1	±0.1	±0.1	-

Polyrox J

Product Details

Product Versions	Polyrox 45-JBP, 53-JBP, 53-JUP
Lead Type	J-shape, passive fixation
U.S. Market Release	Mar 1997
CE Market Release	Jul 1996
Worldwide Distributed Devices	45,400
Registered U.S. Implants	3,740
Estimated Active U.S. Implants	1,760
Unconfirmed Complications	4
Confirmed Malfunctions	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.
Total Survival [%]	100.0	100.0	99.9	99.9	99.9	99.9	99.9	99.8	99.8	99.8	99.8	-
(95 % Confidence Interval)		±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.2	±0.2	±0.2	±0.2	-

Retrox J

Product Details

Product Versions	Retrox 45-JBP, 53-JBP
Lead Type	J-shape, active fixation
U.S. Market Release	Aug 1998
CE Market Release	Mar 1997
Worldwide Distributed Devices	14,000
Registered U.S. Implants	4,240
Estimated Active U.S. Implants	1,960
Unconfirmed Complications	6
Confirmed Malfunctions	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	-
(95 % Confidence Interval)		±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	-

Selox JT

Product Details

Product Versions	Selox JT 45, JT 53
Lead Type	J-shape, passive fixation, bipolar
U.S. Market Release	Nov 2004
CE Market Release	Nov 2004
Worldwide Distributed Devices	38,900
Registered U.S. Implants	4,700
Estimated Active U.S. Implants	4,290
Unconfirmed Complications	4
Confirmed Malfunctions	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.9	99.8	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.1	±0.1	±0.2	-	-	-	-	-	-	-

Selox SR

Product Details

Product Versions	Selox SR 45, SR 53, SR 60
Lead Type	straight, active fixation, bipolar
U.S. Market Release	Mar 2004
CE Market Release	Feb 2004
Worldwide Distributed Devices	103,000
Registered U.S. Implants	14,300
Estimated Active U.S. Implants	11,200
Unconfirmed Complications	24
Confirmed Malfunctions	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.9	99.8	99.7	-	-	-	-	-	-
(95 % Confidence Interval)		±0.1	±0.1	±0.1	±0.1	-	-	-	-	-	-

Selox ST

Product Details

Product Versions	Selox ST 53, ST 60
Lead Type	straight, passive fixation, bipolar
U.S. Market Release	Nov 2004
CE Market Release	Nov 2004
Worldwide Distributed Devices	135,000
Registered U.S. Implants	10,200
Estimated Active U.S. Implants	9,060
Unconfirmed Complications	12
Confirmed Malfunctions	1



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.8	99.7	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.1	±0.1	±0.2	-	-	-	-	-	-	-

Setrox S

Product Details

Product Versions	Setrox S-45, S-53, S-60
Lead Type	straight, active fixation, bipolar
U.S. Market Release	Apr 2006
CE Market Release	Mar 2006
Worldwide Distributed Devices	111,000
Registered U.S. Implants	27,600
Estimated Active U.S. Implants	26,000
Unconfirmed Complications	30
Confirmed Malfunctions	1



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.8	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.0	±0.1	-	-	-	-	-	-	-	-

Synox

Product Details

Product Versions	Synox 60-UP, 53-BP, 60-BP
Lead Type	straight, passive fixation
U.S. Market Release	Sep 1998
CE Market Release	Jul 1996
Worldwide Distributed Devices	150,000
Registered U.S. Implants	17,600
Estimated Active U.S. Implants	9,420
Unconfirmed Complications	7
Confirmed Malfunctions	2



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	100.0	100.0	100.0	99.9	99.9	99.9	99.9	99.9	-
(95 % Confidence Interval)		±0.0	±0.0	±0.0	±0.0	±0.0	±0.1	±0.1	±0.1	±0.1	-

Synox J

Product Details

Product Versions	Synox 45-JBP, 53-JBP
Lead Type	J-shape, passive fixation
U.S. Market Release	Sep 1998
CE Market Release	Jul 1996
Worldwide Distributed Devices	66,700
Registered U.S. Implants	8,170
Estimated Active U.S. Implants	4,850
Unconfirmed Complications	5
Confirmed Malfunctions	1



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	-
(95 % Confidence Interval)		±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	-

Kainox SL

Product Details

Product Versions	Kainox SL 65, 75, 100
Lead Type	dual-coil, passive fixation
U.S. Market Release	Nov 1998
CE Market Release	Sep 1997
Worldwide Distributed Devices	9,600
Registered U.S. Implants	2,500
Estimated Active U.S. Implants	1,440
Unconfirmed Complications	18
Confirmed Malfunctions	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.5	99.4	99.3	99.3	99.2	99.1	99.1	-	-	-
(95 % Confidence Interval)		±0.3	±0.3	±0.4	±0.4	±0.4	±0.5	±0.5	-	-	-

Kentrox RV

Product Details

Product Versions	Kentrox RV 65, -Steroid, 75, -Steroid
Lead Type	single-coil, passive fixation
U.S. Market Release	Mar 2002/Oct 2004
CE Market Release	Jan 2001/Dec 2004
Worldwide Distributed Devices	5,080
Registered U.S. Implants	400
Estimated Active U.S. Implants	268
Unconfirmed Complications	2
Confirmed Malfunctions	1



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.7	99.4	99.4	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.6	±0.6	±0.9	-	-	-	-	-	-	-

Kentrox SL

Product Details

Product Versions	Kentrox SL 65, 75, Kentrox SL 65, 75, 100 Steroid
Lead Type	dual-coil, passive fixation
U.S. Market Release	Oct 2004
CE Market Release	Dec 2003/Dec 2004
Worldwide Distributed Devices	8,280
Registered U.S. Implants	1,020
Estimated Active U.S. Implants	849
Unconfirmed Complications	3
Confirmed Malfunctions	2



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.8	99.7	99.4	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.3	±0.4	±0.7	-	-	-	-	-	-	-

Kentrox SL-S

Product Details

Product Versions	Kentrox SL-S 65/16, 18 Steroid
Lead Type	dual-coil, active fixation
U.S. Market Release	Oct 2004
CE Market Release	Jun 2004
Worldwide Distributed Devices	8,290
Registered U.S. Implants	2,400
Estimated Active U.S. Implants	1,990
Unconfirmed Complications	5
Confirmed Malfunctions	2



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	99.8	99.6	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.1	±0.2	±0.2	-	-	-	-	-	-	-

Linox S

Product Details

Product Versions	Linox S 65, Linox S 75
Lead Type	single-coil, active fixation
U.S. Market Release	Feb 2007
CE Market Release	Mar 2007
Worldwide Distributed Devices	6,090
Registered U.S. Implants	406
Estimated Active U.S. Implants	392
Unconfirmed Complications	0
Confirmed Malfunctions	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	-	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		-	-	-	-	-	-	-	-	-	-

Linox SD

Product Details

Product Versions	Linox SD 65, 75/16,18
Lead Type	dual-coil, active fixation
U.S. Market Release	Apr 2006
CE Market Release	Aug 2006
Worldwide Distributed Devices	20,700
Registered U.S. Implants	6,720
Estimated Active U.S. Implants	6,340
Unconfirmed Complications	21
Confirmed Malfunctions	8



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.5	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.2	-	-	-	-	-	-	-	-	-

Linox TD

Product Details

Product Versions	Linox TD 65, 75, 100/16,18
Lead Type	dual-coil, passive fixation
U.S. Market Release	Oct 2006
CE Market Release	Oct 2006
Worldwide Distributed Devices	6,550
Registered U.S. Implants	749
Estimated Active U.S. Implants	717
Unconfirmed Complications	1
Confirmed Malfunctions	0



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.6	-	-	-	-	-	-	-	-	-
(95 % Confidence Interval)		±0.7	-	-	-	-	-	-	-	-	-

11. Contacting BIOTRONIK

Regarding this Report

BIOTRONIK invites your suggestions and questions related to this Product Performance Report. Please send your comments to:

Worldwide CRM Technical Services:

Phone +49 (0) 30 68905-2200
Fax +49 (0) 30 68905-1960
E-mail PPR@biotronik.com
Address BIOTRONIK GmbH & Co. KG
Attn: Technical Services
Woermannkehre 1
12359 Berlin, Germany

Within the U.S.:

Phone (888) 345-0374
Fax (503) 635-9936
E-mail PPR@biotronik.com
Address BIOTRONIK, Inc.
Attn: Compliance Department
6024 Jean Road
Lake Oswego, OR 97035

Regarding Products

BIOTRONIK invites customers to call the following locations with suggestions, comments or specific questions related to BIOTRONIK products:

Worldwide CRM Technical Services:

Phone +49 (0) 30 68905-2200
Fax +49 (0) 30 68905-1960
E-mail technical.services@biotronik.de
Address BIOTRONIK GmbH & Co KG.
Attn: Technical Services
Woermannkehre 1
12359 Berlin, Germany

Within the U.S.:

Phone (800) 284-6689
Fax (800) 387-2681
E-mail technical.services@biotronik.com
Address BIOTRONIK, Inc.
Attn: Technical Services
6024 Jean Road
Lake Oswego, OR 97035

BIOTRONIK products are available in the following countries:

Asia/Pacific
Australia
Bangladesh
China
Hong Kong
India
Indonesia
Japan
Macao
Malaysia
Maldives
New Zealand
Pakistan
Philippines
Singapore
South Korea
Sri Lanka
Taiwan
Thailand
Vietnam

Europe
Albania
Andorra
Austria
Belgium
Bosnia-Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Kosovo
Latvia
Lithuania
Luxemburg
Macedonia
Malta
Montenegro
Monaco
Netherlands
Norway
Poland
Portugal
Romania
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Turkey
United Kingdom

Africa
Algeria
Benin
Burkina-Faso
Cameroon
Kenya
Morocco
Senegal
South Africa
Sudan
Tunisia

Russia and CIS (Commonwealth of Independent States)
Armenia
Azerbaijan
Belarus
Georgia
Kazakhstan
Moldova
Russia
Ukraine
Uzbekistan

Middle East
Bahrain
Egypt
Iran
Iraq
Israel
Jordan
Kuwait
Lebanon
Libya
Qatar
Saudi Arabia
United Arab Emirates
Yemen

Latin America
ABC Islands
Argentina
Bolivia
Brazil
Chile
Colombia
Costa Rica
Cuba
Dominican Republic
El Salvador
Guadeloupe
Guatemala
Guyana
Haiti
Honduras
Martinique
Mexico
Nicaragua
Panama
Paraguay
Peru
Puerto Rico
Uruguay
Venezuela

North America
USA
Canada

Worldwide
BIOTRONIK GmbH & Co. KG
Woermannkehre 1
12359 Berlin · Germany
Tel +49 (0) 30 68905–0
Fax +49 (0) 30 685 28 04
www.biotronik.com

U.S.
BIOTRONIK, Inc.
6024 Jean Road
Lake Oswego, OR 97035-05369
Tel (800) 547-0394 (24-hour)
Fax (800) 291-0470
www.biotronik.com

CE

BIOTRONIK
excellence for life

359684/E/902